Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
Compositions and methods for repairing or regenerating damaged tissue are disclosed. In particular, the invention relates to methods of delivering secreted factors from stem cells to tissues in order to immobilize and concentrate such secreted factors at or under the surface of damaged tissue to promote tissue regeneration.
1 . A method of accelerating wound healing and reducing neovascularization and scar formation, in damaged tissue in a subject, the method comprising:
a) collecting a bone marrow-derived mesenchymal stem cell (MSC) secretome from a mesenchymal stem cell;
b) mixing the bone marrow-derived mesenchymal stem cell (MSC) secretome from the stem cell with a solution comprising at least one biocompatible polymer or biopolymer to form a mixture; wherein said at least one biocompatible polymer or biopolymer comprises a mixture of hyaluronic acid and chondroitin sulfate; and
c) applying the mixture to the damaged tissue, wherein the bone marrow-derived mesenchymal stem cell (MSC) secretome from the stem cell accelerates healing at or under the surface of the damaged tissue; wherein the damaged tissue is ocular tissue, wherein the ocular tissue is corneal or stromal tissue;
and wherein the bone marrow-derived MSC secretome reduces neovascularization and scar formation in the damaged tissue.
2 . The method of claim 1 , wherein said at least one biocompatible polymer or biopolymer encapsulates the bone marrow-derived MSC secretome in step b).
3 . The method of claim 1 , wherein said at least one biocompatible polymer or biopolymer is adherent to tissue.
4 . The method of claim 1 , wherein said at least one biocompatible polymer or biopolymer forms a hydrogel encapsulating the bone marrow-derived MSC secretome in step b).
5 . The method of claim 1 , wherein the subject is human.
6 . The method of claim 1 , further comprising preparing the damaged tissue prior to treating the subject by exfoliation or debridement of fibrotic or necrotic tissue.
7 . The method of claim 1 , further comprising administering one or more therapeutic agents to the subject.
8 . The method of claim 7 , wherein the one or more therapeutic agents are selected from the group consisting of an analgesic agent, an anti-inflammatory agent, and an anesthetic.
9 . The method of claim 1 , wherein step c) is repeated for multiple cycles—for a time period sufficient to effect at least a partial healing of the damaged tissue, or wherein step c) is repeated for multiple cycles—for a time period sufficient to effect a complete healing of the damaged tissue.
10 . The method of claim 1 , wherein damage to the ocular tissue is caused by a chemical burn, severe dry eye, keratoconjunctivitis sicca, Sjogren's syndrome, ocular graft-versus-host disease, ocular cicatricial pemphigoid, Stevens-Johnson syndrome, physical trauma, neurotrophic keratopathy, a recurrent corneal erosion, a corneal ulcer, exposure keratopathy, retinal disease or degeneration, or optic nerve damage or degeneration.
11 . The method of claim 4 , wherein the hydrogel molds to the contours of the ocular tissue surface.